Abstract
Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have